Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease

Imagem de Miniatura
Arquivos
art_GOMES_Neurological_status_predicts_response_to_alphablockers_in_men_2014.PDF (276.25 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2014
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
NITTI, Victor W.
Citação
CLINICS, v.69, n.12, p.817-822, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: To evaluate predictors of the response to doxazosin, a selective alpha-adrenoceptor antagonist, when used for the treatment of lower urinary tract symptoms in men with Parkinson's disease. METHODS: In a prospective study, 33 consecutive men (mean age 59.2 +/- 7.0 years) with Parkinson's disease and lower urinary tract symptoms were evaluated. Neurological dysfunction was assessed with the Unified Parkinson's Disease Rating Scale. Urological assessment was performed at baseline and after 12 weeks of treatment with 4 mg/day of extended-release doxazosin, including symptom evaluation with the International Continence Society male short-form questionnaire, an assessment of the impact of lower urinary tract symptoms on quality of life and urodynamics. Clinical and urodynamic predictors of response were specifically evaluated. RESULTS: Compared with the score at baseline, the total International Continence Society male short-form score was reduced after doxazosin administration, from 17.4 +/- 7.5 to 11.1 +/- 6.9 (p<0.001). The impact of lower urinary tract symptoms on quality of life was also significantly reduced, from 1.8 +/- 1.1 to 1.0 +/- 1.0 (p<0.001) and the maximum urinary flow varied from 9.3 +/- 4.4 to 11.2 +/- 4.6 ml/s (p = 0.025). The severity of neurological impairment was the only predictor of the clinical response. Additionally, patients with a Unified Parkinson's Disease Rating Scale score lower than 70 had a significantly higher chance of clinical improvement with doxazosin treatment than those with higher Unified Parkinson's Disease Rating Scale scores did (RR = 3.10, 95% CI = [1.15 to 5.37], p = 0.011). CONCLUSIONS: Doxazosin resulted in the improvement of lower urinary tract symptoms and the maximum flow rate and was well tolerated in men with Parkinson's disease. The response to treatment is dependent on the severity of neurological disability.
Palavras-chave
Lower Urinary Tract Symptoms, Parkinson's Disease, Urodynamics, Doxazosin
URI
https://observatorio.fm.usp.br/handle/OPI/9237
Referências
  1. Araki I, 2000, J NEUROL NEUROSUR PS, V68, P429, DOI 10.1136/jnnp.68.4.429
  2. Araki I, 2000, J UROLOGY, V164, P1640, DOI 10.1016/S0022-5347(05)67048-6
  3. CHRISTMAS TJ, 1988, LANCET, V2, P1451
  4. Donovan JL, 2000, J UROLOGY, V164, P1948, DOI 10.1016/S0022-5347(05)66926-1
  5. Fowler CJ, 2001, FUNCT NEUROL, V16, P277
  6. GALLOWAY NTM, 1983, BRIT J UROL, V55, P691, DOI 10.1111/j.1464-410X.1983.tb03406.x
  7. Hampel C, 2002, J UROLOGY, V167, P1513, DOI 10.1016/S0022-5347(05)65355-4
  8. Kortmann BBM, 2003, UROLOGY, V62, P1, DOI 10.1016/S0090-4295(02)02113-1
  9. Narayan P, 2003, J UROLOGY, V170, P498, DOI 10.1097/01.ju.0000076140.68657.fd
  10. Oelke M, 2013, EUR UROL, V64, P118, DOI 10.1016/j.eururo.2013.03.004
  11. PAVLAKIS AJ, 1983, J UROLOGY, V129, P80
  12. Roehrborn CG, 2002, CAMPBELLS UROLOGY, P1297
  13. Rossi C, 2001, J UROLOGY, V165, P38, DOI 10.1097/00005392-200101000-00010
  14. Roth B, 2009, J UROLOGY, V181, P2209, DOI 10.1016/j.juro.2009.01.049
  15. Sakakibara R, 2001, J NEUROL NEUROSUR PS, V71, P600, DOI 10.1136/jnnp.71.5.600
  16. Sakakibara R, 2001, AUTON NEUROSCI-BASIC, V92, P76, DOI 10.1016/S1566-0702(01)00295-8
  17. Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8
  18. Sammour ZM, 2009, NEUROUROL URODYNAM, V28, P510, DOI 10.1002/nau.20681
  19. SCHAFER W, 1990, UROL CLIN N AM, V17, P553
  20. Schapira A, 2004, LANCET NEUROL, V3, P362, DOI 10.1016/S1474-4422(04)00769-0
  21. Seki S, 2001, NEUROUROL URODYNAM, V20, P105, DOI 10.1002/1520-6777(2001)20:1<105::AID-NAU12>3.0.CO;2-9
  22. STASKIN DS, 1988, J UROLOGY, V140, P117
  23. Stohrer M, 2009, EUR UROL, V56, P81, DOI 10.1016/j.eururo.2009.04.028
  24. Winge K, 2006, NEUROUROL URODYNAM, V25, P116, DOI 10.1002/nau.20193
  25. Winge K, 2004, NEUROUROL URODYNAM, V23, P689, DOI 10.1002/nau.20054
  26. Yoshiyama M, 2001, AM J PHYSIOL-REG I, V280, pR1414

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/45
Artigos e Materiais de Revistas Científicas - LIM/55